Design of Phase II cancer trials evaluating survival probabilities

BMC Medical Research Methodology

Volumn 3, Issue , 2003, Pages 1-12

  Case, L Douglas ^a   Morgan, Timothy M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; COST CONTROL; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PLANNING; PROBABILITY; SAMPLE SIZE; SIMULATION; COMPUTER SIMULATION; EVALUATION; HUMAN; STATISTICAL MODEL; STATISTICS; SURVIVAL;

CLINICAL TRIALS, PHASE II; COMPUTER SIMULATION; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 3042809745     PISSN: 14712288     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2288-3-6     Document Type: Article

References (26)

1. Gehan EA The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent Journal of Chronic Diseases 1961, 13:346-353
2. Fleming TR One sample multiple testing procedure for phase II clinical trials Biometrics 1982, 38:143-151
3. Chang MN, Therneau TM, Wieand HS and Cha SS Designs for group sequential phase II clinical trials Biometrics 1987, 43:865-874
4. Simon R Optimal two-stage designs for phase II clinical trials Controlled Clinical Trials 1989, 10:1-10
5. Green SJ and Dahlberg S Planned versus attained design in phase II clinical trials Statistics in Medicine 1992, 11:853-862
6. Thall PF and Richard Simon Practical Bayesian guidelines for phase IIB clinical trials Biometrics 1994, 50:337-349
7. Chen TT Optimal three-stage designs for phase II cancer clinical trials Statistics in Medicine 1997, 16:2701-2711
8. Heitjan DF Bayesian interim analysis of phase II cancer clinical trials Statistics in Medicine 1997, 16:1791-1802
9. Herndon JE II A design alternative for two-stage, phase II, multicenter cancer clinical trials Controlled Clinical Trials 1998, 19:440-450
10. Chen TT and Ng T-H Optimal flexible designs in phase II clinical trials Statistics in Medicine 1998, 17:2301-2312
11. Colton T and McPherson K Two-stage plans compared with fixed-sample-size and Wald SPRT plans J Am Stat Assoc 1976, 71:80-86
12. Landis SH, Murray T, Bolden S and Wingo PA Cancer Statistics, 1998 CA: A Cancer Journal for Clinicians 1998, 48:6-29
13. Lawrence T Gemcitabine as a radiation sensitizer Sem Oncol 1995, 22:68-71
14. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B and Tarassoff PG Phase II trial of gemcitabine (2′2′-difluoro-2′-deoxycytidine) in patients with adenocarcinoma of the pancreas Investigational New Drugs 1994, 12:29-34
15. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff R, Nelson R, Dorr FA, Stephens CD and Von Hoff DD Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 1997, 15:2403-2413
16. Blackstock AW and Bernard SA Twice weekly gemcitabine and concurrent radiation: laboratory studies supporting phase I clinical trials in pancreatic cancer Can Conf 1999, 3:2-6
17. Kaplan EL and Meier P Nonparametric estimation from incomplete observations J Am Stat Assoc 1958, 53:457-481
18. Nelson W Hazard plotting for incomplete failure data J Quality Technology 1969, 1:27-52
19. Jennison C and Turnbull BW Group Sequential Designs with Applications to Clinical Trials Boca Raton, Chapman & Hall/CRC 2000,
20. Lan KKG and DeMets DL Discrete sequential boundaries for clinical trials Biometrika 1983, 70:659-663
21. Lin DY, Shen L, Ying Z and Breslow NE Group sequential designs for monitoring survival probabilities Biometrics 1996, 52:1033-1042
22. Donnely TG Algorithm 462 - Bivariate normal distribution [S15] Comm ACM 1973, 16:638
23. Brent R Algorithms for Minimization without Derivatives Englewood Cliffs, Prentice Hall 1973,
24. Follmann DA and Albert PS Bayesian monitoring of event rates with censored data Biometrics 1999, 55:603-607
25. Cheung YK and Thall PF Monitoring the rates of composite events with censored data in phase II clinical trials Biometrics 2002, 58:89-97
26. Case LD and Morgan TM Duration of accrual and follow-up for two-stage clinical trials Lifetime Data Analysis 2001, 7:21-37